文献速递神经肿瘤

无功能垂体神经内分泌肿瘤的临床病理特征与结局:转录因子驱动亚型分析

Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.
PubMed 文献 · J Neurooncol · 2026-01-08

本研究回顾性分析409例无功能垂体神经内分泌肿瘤患者,按转录因子表达分为SF1、TPIT、PIT1及无明确谱系四个亚组。中位随访801天,发现PIT1和TPIT亚组无瘤生存期更短,尤其PIT1亚组,提示转录因子分型与临床特征及短期预后相关,建议对这两个亚组加强术后监测。

要点

  • 无功能PitNET按转录因子分型存在临床与预后异质性
  • TPIT亚组肿瘤最大且侵袭性最强
  • PIT1与TPIT亚组无瘤生存期更短,需加强术后监测

核心结论

  • 转录因子表达与无功能PitNET distinct临床特征和短期结局相关。
  • PIT1和TPIT谱系与更短的无瘤生存期相关,尤其PIT1亚组。
  • 建议对PIT1和TPIT亚组加强术后监测。

研究设计与样本

  • 回顾性收集本院诊断的无功能PitNET患者临床数据。
  • 按转录因子表达分为SF1、TPIT、PIT1及无明确谱系亚组进行比较。
  • 共纳入409例患者,男202例(49.4%),女207例(50.6%)。
  • 预后数据通过术后门诊记录和电话随访获得,中位随访801天。

主要发现

  • SF1亚组245例(59.9%),TPIT亚组101例(24.7%),PIT1亚组39例(9.5%),无明确谱系组24例(5.9%)。
  • SF1亚组与脂代谢紊乱相关。
  • TPIT亚组肿瘤最大且侵袭性最强。
  • PIT1和无明确谱系组更易出现高泌乳素血症和溢乳,侵犯海绵窦倾向较低。
  • PIT1和TPIT亚组无瘤生存期更短,尤其PIT1亚组。

关键数值与推荐

  • 无功能PitNET按转录因子分为SF1、TPIT、PIT1及无明确谱系四个亚组。
  • PIT1和TPIT谱系患者预后较差,建议加强术后监测。

临床怎么用

  • 对无功能PitNET进行转录因子分型有助于识别预后较差亚组。
  • PIT1和TPIT亚组患者术后应加强随访监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the differences in clinicopathological features and outcomes of non-functioning pituitary neuroendocrine tumors (PitNETs) based on transcription factor expression. METHODS: Clinical data were collected from patients diagnosed with non-functioning PitNETs at our hospital. Tumors were classified into transcription factor-based subgroups for comparison. Clinical characteristics were analyzed across these subgroups, and prognostic data were obtained through postoperative outpatient records and telephone follow-ups. RESULTS: A total of 409 patients were included, comprising 202 males (49.4%) and 207 females (50.6%). Of these, 245 (59.9%), 101 (24.7%), 39 (9.5%), and 24 (5.9%) patients were classified into the steroidogenic factor-1 (SF1), T-box transcription factor 19 (TPIT), POU class 1 homeobox 1 (PIT1), and no distinct lineage groups, respectively. The SF1 subgroup was associated with lipid metabolism disorders. The TPIT subgroup had the largest and most invasive tumors. Patients in the PIT1 and no distinct lineage groups were more likely to present with hyperprolactinemia and galactorrhea and showed a lower tendency to invade the cavernous sinus. The median follow-up duration was 801 days. The PIT1 and TPIT subgroups had shorter tumor-free survival, particularly the former. Further survival analysis revealed that patients with TPIT and PIT1 lineages had poorer prognoses. CONCLUSIONS: Transcription factor expression was associated with distinct clinical features and short-term outcomes. The PIT1 and TPIT lineages were linked to shorter tumor-free survival. Enhanced postoperative surveillance is recommended for these subgroups. These findings underscore the clinical and prognostic heterogeneity of non-functioning PitNETs.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hu W, Rao Q, Zhu D, et al. Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis. J Neurooncol. 2026. PMID: 41504789. doi:10.1007/s11060-025-05418-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。